Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
To investigate the association between valproate metabolism (VPA) and VPA-induced hyperammonemia together with the contribution of VPA hepatotoxicity risk factors such as young age, polypharmacy, and high serum VPA levels to VPA-induced hyperammonemia, plasma ammonia (NH3) levels, serum levels of VPA and its metabolites, and biochemical parameters were determined in 98 patients treated with VPA (53 monopharmacy cases and 45 polypharmacy cases). In monopharmacy patients, plasma NH3 levels did not depend on age, VPA dosage or serum levels. Serum level of 2-propyl-4-pentenoic acid (4-en) showed a negative correlation with plasma NH3 level in the monopharmacy group. In polypharmacy patients, plasma NH3 levels, serum glutamic pyruvic transaminase, and gamma-glutamyl-transpeptidase were significantly higher, while level/dose VPA ratio, 2-en-VPA serum level, and bilirubin were significantly lower than those in monopharmacy patients. These results suggest that young age and relatively high VPA serum levels within the therapeutic range were unlikely to be risk factors for common hyperammonemia associated with VPA therapy and that 4-en was not causally related to this adverse effect. The decreased serum level of 2-en-VPA in polypharmacy patients may be a reflection of a certain mitochondrial dysfunction, which might be a mechanism of the increased NH3 levels. The changes in biochemical parameters in polypharmacy patients were considered results of the enzyme-inducing activity of coadministered antiepileptic drugs (AEDs).
Department of Neuropsychiatry, Hirosaki University, Japan.
T
T
Kondo
M
M
Ishida
S
S
Kaneko
T
T
Hirano
K
K
Otani
Y
Y
Fukushima
H
H
Muranaka
N
N
Koide
M
M
Yokoyama
S
S
Nakata
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000410:Alanine Transaminase / Q000097:blood; D000641:Ammonia / Q000097:blood*; D000927:Anticonvulsants / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects* / Q000097:blood; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D014635:Valproic Acid / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
D000927:Anticonvulsants; D005229:Fatty Acids, Monounsaturated; C014168:2-propyl-2-pentenoic acid; D014635:Valproic Acid; D000641:Ammonia; D005723:gamma-Glutamyltransferase; D000410:Alanine Transaminase; D001663:Bilirubin